Dormicum

• Anesthetics, Intravenous
• Anti-anxiety Agents
• Hypnotics and Sedatives
• Adjuvants, Anesthesia
• GABA Modulators
• ATC:N05CD08

• Dea No. 2884
• Dormicum
• Midazolam Base
• Midazolam Hcl
• Midazolamum [Inn-Latin]
• Versed

• No information avaliable

C₁₈H₁₃ClFN₃

http://www.rxlist.com/cgi/generic2/versedsyr.htm

Dormicum MSDS

No information avaliable

325.767 g/mol

159 ^oC

40.0 mg/ml

Solid

3.868

Liquid; Solution

For use in pediatric patients for sedation, anxiolysis, and amnesia prior to diagnostic, therapeutic, or endoscopic procedures or before induction of anesthesia.

Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.

Rapidly absorbed after oral administration (absolute bioavailability of the midazolam syrup in pediatric patients is about 36%, and intramuscular is greater than 90%).

LD₅₀=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.

Humans and other mammals